Comparative Pharmacology
Head-to-head clinical analysis: ROBAXISAL versus TRANCOPAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROBAXISAL versus TRANCOPAL.
ROBAXISAL vs TRANCOPAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is not fully understood, but it is believed to involve general central nervous system depression and inhibition of polysynaptic reflexes in the spinal cord. Aspirin inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and anti-inflammatory effects, and also irreversibly inhibits platelet aggregation.
Trancopal (chlormezanone) is a centrally acting muscle relaxant and anxiolytic. Its exact mechanism is not fully understood, but it is believed to act on the central nervous system by depressing polysynaptic reflexes and possibly through GABAergic modulation.
Oral: 2 tablets (methocarbamol 750 mg / aspirin 650 mg) 4 times daily.
200-400 mg orally every 6 hours as needed for acute musculoskeletal pain; maximum 1.6 g per day.
None Documented
None Documented
Methocarbamol: 1.0–2.0 hours (prolonged in renal impairment); guaifenesin: approximately 1 hour.
Terminal elimination half-life: 20-30 hours in healthy adults. Prolonged in hepatic impairment (up to 60 hours).
Methocarbamol: renal (primarily as glucuronide and sulfate conjugates, with <2% unchanged); guaifenesin: renal (metabolites, <1% unchanged). No significant biliary/fecal elimination.
Primarily renal: ~95% as metabolites (glucuronides, sulfate conjugates) with <1% unchanged. Fecal: <5%.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant